Webinar: New Ways of Evaluating the Tumor Immune Microenvironment-4

T-cell redirecting therapies with gene-engineered CAR T-cells and T-cell engaging bispecific antibodies (bsAb) are showing promising results in clinical trials.https://www.creative-biolabs.com/bsab/new-ways-of-evaluating-the-tumor-immune-microenvironment-from-bench-to-bedside.html